Abstract

BillionToOne, Inc. will report its third-quarter 2026 results on November 4, 2026 Post-Mkt; this preview compiles consensus forecasts for revenue, profitability, and adjusted EPS, reviews the prior quarter’s performance and business mix, and highlights the principal operational factors and analyst perspectives expected to shape the upcoming print and immediate stock reaction.

Market Forecast

Consensus expectations for the current quarter call for revenue of 115.59 million US dollars, implying 39.57% year-over-year growth, with EBIT near 7.68 million US dollars, up 4.83% year over year, and adjusted EPS of $0.15, reflecting a 71.15% year-over-year decline. There is no specific gross profit margin or net margin forecast disclosed in the compiled dataset, but the projection set implies top-line expansion with compressed per-share earnings.

The core revenue engine is expected to remain concentrated in prenatal genetics testing, with a stable-to-improving margin profile tied to product mix and payer coverage, while oncology continues to scale from a smaller base with differentiated product launches. The oncology business is highlighted as the most promising growth contributor: it delivered 13.66 million US dollars last quarter and, earlier in the year, posted quadruple-digit year-over-year growth off a smaller base to reach 10.70 million US dollars in the first quarter, signaling momentum into the back half.

Last Quarter Review

BillionToOne, Inc. reported last-quarter revenue of 109.45 million US dollars, a gross profit margin of 70.45%, net profit attributable to shareholders of 8.05 million US dollars, a net profit margin of 7.36%, and adjusted EPS of $0.15; year-over-year deltas were not disclosed in the reported dataset.

A notable highlight was the robust gross profit margin above 70%, underscoring favorable pricing and product-mix execution. The main business mix featured prenatal products at 94.25 million US dollars, oncology at 13.66 million US dollars, and clinical-trial support services at 1.54 million US dollars, while year-over-year comparison data for these segments was not available in the same dataset.

Current Quarter Outlook

Main Business: Prenatal Testing and Mix Discipline

Management’s sustained emphasis on unit economics and payer alignment continues to underpin the prenatal franchise’s revenue scale and margin resilience. With last quarter’s prenatal revenue at 94.25 million US dollars, the line item remains the principal driver of consolidated top-line. The upcoming quarter’s projections indicate that prenatal will again carry the largest share of revenue, aided by steady utilization, improved contracting coverage, and incremental contributions from upgraded workflows and confirmatory offerings. Within this context, maintaining a high-60s to low-70s gross-margin profile will hinge on balancing average selling price discipline and throughput, especially as the company navigates broader test adoption dynamics and case mix.

Enrollment and coverage breadth are tangible contributors to the unit-economics equation in the period under review. Expanded in-network arrangements earlier in the year translated to broader contracted lives, a dynamic that historically correlates with faster test intake conversion and better collections. The company’s prior update about expanding contracted lives to a substantial nationwide footprint sets up a supportive backdrop for both volume and revenue per order. As a result, the prenatal segment’s revenue cadence in the current quarter should be primarily a function of utilization trends, collections performance, and ongoing channel penetration among obstetrics and maternal-fetal medicine practices.

The margin conversation for the quarter centers on two levers: mix shift and operational intensity. On mix, a pivot toward higher-value offerings and confirmatory workflows tends to support gross margin above 70%, consistent with the recent quarter’s outcome. On operating intensity, scaling logistics, lab operations, and support infrastructure can pressure near-term operating margin; the prenatal segment’s ability to absorb these costs while protecting ASP will be crucial for the print. With consensus expecting robust revenue growth but a pronounced year-over-year decline in EPS, the market appears to be bracing for rising operating expenses, likely reflecting continued investment in growth and product development tied to both core prenatal and adjacent offerings.

Most Promising Business: Oncology Expansion and Product Launches

Oncology revenue of 13.66 million US dollars last quarter illustrates a scaling second act for the company, and earlier segment disclosures this year pointed to an accelerated growth curve. The oncology portfolio has been augmented by product updates and launches that target clinical decision points, including recent additions designed to predict tissue of origin and broaden genomic coverage across therapeutically relevant genes. This cadence of innovation, together with early-stage commercial traction, frames oncology as the company’s most promising near-term growth contributor and a meaningful medium-term margin enhancer once scale effects materialize.

The near-term investment case for oncology turns on three elements: product breadth, clinical usability, and payer convertibility. Product breadth has expanded via a broader gene panel and an add-on test that addresses a key diagnostic gap in cases with uncertain primaries, enabling more tailored downstream care options. In terms of usability, workflows that fit into oncologists’ existing routines can accelerate adoption; the reported enhancements aim to reduce friction in ordering and interpretation. Payer convertibility—i.e., moving from pilot or out-of-network to contracted coverage—is the bridge to durable revenue; evidence generation and guideline momentum typically support this path. Earlier this year, oncology revenue also grew sharply year over year off a smaller base, rising to 10.70 million US dollars in the first quarter, and the current quarter’s forecasted revenue growth at the corporate level suggests oncology remains a growing slice of the mix.

Despite its promise, oncology can introduce near-term EPS volatility as commercialization and evidence-generation costs front-load ahead of scale benefits. The consensus EPS forecast implies that investments in sales infrastructure, medical affairs, and validation studies are likely continuing. If the quarter shows stronger-than-expected oncology revenue while controlling for incremental operating spend, upside to EBIT could follow even as per-share earnings remain capped by higher operating expense. This creates a setup where revenue beats can coexist with EPS near consensus, consistent with the forecast profile of top-line outperformance and muted net-income flow-through.

Key Stock-Price Drivers This Quarter: Revenue Momentum, Margin Bridge, and Opex Trajectory

The primary stock driver into the print is top-line momentum relative to the 115.59 million US dollars consensus revenue. A beat on volumes or ASPs in the prenatal segment, coupled with incremental oncology contribution, can anchor a favorable reaction if management commentary supports durability into the fourth quarter. Conversely, a line-with-expectations revenue outcome may still be viewed constructively if the company articulates a credible backlog, conversion funnel, and payer pipeline, given the importance of sustained sequential growth at this stage.

The margin bridge from gross profit to EBIT will be scrutinized in detail. The company delivered a 70.45% gross margin last quarter, and the revenue mix trend suggests conditions to support a similar or slightly improved level, assuming product mix and collections hold. However, the EPS forecast’s sharp year-over-year decline implies operating expenses are rising faster than revenue, potentially due to continued oncology scaling, product rollouts, and field investments. Investors will look to see whether operating expense growth is peaking or continuing, and whether productivity gains in sales and operations are beginning to offset the initial investment wave.

Guidance and qualitative commentary represent another meaningful driver. Earlier in the year, management widened its full-year revenue outlook, reflecting confidence in pipeline conversion and product mix. Any reiterated or updated outlook can recalibrate the stock’s near-term narrative by clarifying the balance between growth and profitability. If management underscores a path to sustain gross margins in the 70% range while moderating opex intensity, the implied EBIT trajectory could surpass the 7.68 million US dollars baseline, an outcome the market would likely interpret as constructive even if EPS remains constrained near term.

Analyst Opinions

Analyst sentiment has been predominantly bullish in the period leading up to the report, with at least four Buy ratings versus a single Hold among the notable updates captured, indicating a clear positive skew heading into the quarter. J.P. Morgan reiterated a Buy rating and a 145 US dollars price target, highlighting the company’s execution on revenue growth and an expanding total addressable opportunity for its differentiated testing portfolio. William Blair reaffirmed its Buy view, citing a strong prior-quarter outturn, visible growth through 2027, and relative valuation support compared with higher-growth peer groups. Canaccord Genuity initiated at Buy with a 120 US dollars target, reflecting confidence in continued adoption trends and a favorable risk-reward setup, while Wells Fargo maintained a Hold stance with a 90 US dollars target, positioning itself more cautiously on near-term EPS conversion even as it acknowledges the revenue trajectory.

The dominant Buy cohort’s perspective converges on three themes for the current print. First, revenue growth is expected to remain robust at approximately 39.57% year over year, supported by steady prenatal volumes and mix uplift, as well as incremental oncology contributions. Second, analysts anticipate that gross margin can remain in a healthy zone, with variability driven primarily by product mix and payer dynamics rather than cost inflation in lab operations. Third, EPS is modeled to compress year over year due to ongoing investment across commercialization, evidence generation, and expansion of the field infrastructure—costs that the bullish camp generally characterizes as necessary to secure medium-term growth and operating leverage.

Within that framework, the Buy camp is broadly looking for an outcome along three lines: revenue at or above 115.59 million US dollars, gross margin holding around 70%, and EBIT performance tracking close to or above the 7.68 million US dollars projection. A scenario in which the company meets or modestly exceeds revenue, affirms sustained gross margins, and signals improved operating efficiency could reinforce the bullish narrative even if adjusted EPS lands near the $0.15 consensus. Conversely, if revenue meets but operating expenses run ahead of plan—pressuring EBIT—bullish analysts may still maintain their long-term stance provided management articulates a clear timetable for opex normalization and outlines concrete milestones for oncology scaling.

The bull-bear divide is most visible in near-term profitability expectations rather than the durability of growth. The Hold view emphasizes that EPS conversion remains a gating factor for near-term valuation expansion. However, the majority Buy perspective prioritizes the sustainability of high-teens to low-20s EBIT growth as scale economies kick in and sees current multiples as justified by a credible path to operating leverage. The bullish camp also points to supportive datapoints from earlier this year, including significant contracted coverage expansion and new product introductions, as tangible catalysts for sustained revenue growth.

Taken together, the balance of opinions leans decisively positive. The Buy-aligned institutions expect that strong revenue execution—anchored by prenatal and amplified by oncology—along with resilient gross margins and a line of sight to operating leverage, will enable the company to meet or exceed key consensus benchmarks. While they acknowledge the EPS headwind this quarter, their constructive stance rests on the premise that reinvestment is laying the groundwork for multi-quarter growth and improved profitability, making the growth-to-profitability handoff the central storyline to watch as the company reports on November 4, 2026 Post-Mkt.